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XI-006 induces potent p53-
independent apoptosis in Ewing 
sarcoma
Kathleen I. Pishas1,2, Alaknanda Adwal2, Susan J. Neuhaus3, Mark T. Clayer4, 
Gelareh Farshid5, Alexander H. Staudacher6,7 & David F. Callen1,2
There is an imperious need for the development of novel therapeutics for the treatment of Ewing 
sarcoma, the second most prevalent solid bone tumour observed in children and young adolescents. 
Recently, a 4-nitrobenzofuroxan derivative, XI-006 (NSC207895) was shown to diminish MDM4 
promoter activity in breast cancer cell lines. As amplification of MDM4 is frequently observed in 
sarcomas, this study examined the therapeutic potential of XI-006 for the treatment of Ewing and 
osteosarcoma. XI-006 treatment of Ewing and osteosarcoma cell lines (n = 11) resulted in rapid and 
potent apoptosis at low micro-molar concentrations specifically in Ewing sarcoma cell lines (48 hr 
IC50 0.099–1.61 μM). Unexpectedly, apoptotic response was not dependent on MDM4 mRNA/protein 
levels or TP53 status. Alkaline/neutral comet and γH2AX immunofluorescence assays revealed 
that the cytotoxic effects of XI-006 could not be attributed to the induction of DNA damage. RNA 
expression analysis revealed that the mechanism of action of XI-006 could be accredited to the 
inhibition of cell division and cycle regulators such as KIF20A and GPSM2. Finally, potent synergy 
between XI-006 and olaparib (PARP inhibitor) were observed due to the down-regulation of Mre11. 
Our findings suggest that XI-006 represents a novel therapeutic intervention for the treatment of 
Ewing sarcoma.
Sarcomas are a group of rare malignancies that affect approximately 200,000 individuals worldwide each 
year1. Exemplifying the heterogeneous nature of this malignancy type, approximately 50 distinct histo-
logical subtypes of sarcoma have been identified to date, ranging from indolent to highly invasive and 
metastatic2. The introduction of cytotoxic chemotherapeutic agents such as doxorubicin in the 1960’s for 
chemo-sensitive subtypes was a paradigm shift in oncology practice, however current multi-agent chem-
otherapeutic regimens are associated with significant cumulative and late toxicities. With the exception 
of gastrointestinal stromal tumours (GIST), limited progress in the management of sarcomas has been 
achieved over the past few decades years. For this reason, the advent of novel and targeted therapeutics 
with favourable efficacy and toxicity profiles are eagerly awaited, especially for those 20–40% of patients 
with non-responding, unresectable or metastatic disease.
Cancer is a multifaceted process that can arise due to the activation of proto-oncogenes and/or inac-
tivation of tumour suppressor genes. The development of novel anti-cancer agents, specifically those 
focused on targeting oncogene addiction has undergone a dramatic renaissance over the past decade. 
One particular oncogene which has gained significant interest is MDM4 (Mouse Double Minute 4), a 
structural homologue of MDM2, thought to promote tumourigenesis via its ability to inhibit the tumour 
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suppressor function of TP533. In keeping with this hypothesis, amplification and/or overexpression 
of MDM4 has been documented across a wide spectrum of tumours including cutaneous melanoma 
(68.5%)4, retinoblastoma (65%)5, head and neck squamous carcinoma (50%)6 , breast (19%)3 and sarcoma 
(17%)7,8. In particular, MDM4 copy number gain was documented in 54% of conventional, intramed-
ullary, high-grade osteosarcomas and 33% of parosteal osteosarcomas9. Furthermore, amplification of 
MDM4 defined as > 3 fold was shown to be a distinctive attribute of Ewing, synovial and osteosarcomas, 
with amplification observed in 50%, 44% and 35% of tumour samples respectively8. Prevailing evidence 
suggests that MDM4 primarily represses the transcriptional activity of p53 by binding its trans-activation 
domain. However, although displaying no intrinsic E3 ubiquitin ligase activity, MDM4 can also regulate 
p53 stability by promoting MDM2-mediated degradation10,11.
Owing to the prevalence of MDM4 genomic amplification/mRNA overexpression in human cancers, 
several strategies aimed at inhibiting the oncogenic activity of MDM4 have been explored. Although 
a selective MDM4 small-molecule inhibitor does not currently exist, the first reported p53-MDM4 
antagonist, SJ-172550, did exhibit cytotoxicity in retinoblastoma cells12. However, the thiol reactivity of 
SJ-172550 precludes its chemical scaffold from further development13. Recently, a peptide antagonist of 
the p53-MDM4 interaction, designated SAH-p53-8 has been developed. This stapled peptide possesses 
substantially improved pharmacokinetic profiles compared to non-stapled peptide counterparts, and 
has nano-molar binding affinity to the N-terminal p53-binding pocket of both MDM2 and MDM414. 
However, the bioavailability of stapled peptides and their potential as therapeutic agents has been ques-
tioned. Small molecules are considered more desirable for cancer therapy as their cellular uptake is 
dependent on passive diffusion, whereas stapled peptides such as SAH-p53-8 require pinocytosis, which 
is less effective15. Indeed, this is highlighted by the fact that high concentrations of SAH-p53-8 (15–
30 μ M) were required to induce significant cytotoxicity in melanoma cells in vitro, uptake was attenuated 
in the presence of serum, and complete regression of xenograft tumours was not achieved4,16. Given 
that aberrant transcription of MDM4 can be attributed to its overexpression in cancer17, Wang and 
colleagues employed a high-throughput drug screening strategy to identify small molecules that could 
mitigate MDM4 promoter activity. A 4-nitrobenzofuroxan derivative, designated XI-006 (NSC207895) 
was identified and was shown to repress MDM4 promoter activity resulting in decreased MDM4 mRNA 
and protein expression and cell viability in MDM4 amplified breast cancer cell lines18.
To our knowledge, no studies have hitherto directly addressed whether repression of MDM4 activity 
can represent a novel therapeutic strategy for the treatment of sarcomas. In particular, as MDM4 ampli-
fication is a characteristic of both Ewing and osteosarcoma, this study has examined the biological effects 
of XI-006 both as a single agent and in combination with standard chemotherapeutic agents and olaparib 
(PARP inhibitor) in a comprehensive panel of Ewing and osteosarcoma cell lines in vitro. Specifically, 
treatment of Ewing sarcoma cell lines resulted in potent apoptosis that was remarkably not dependent 
on MDM4 mRNA or protein levels or TP53 status.
Results
MDM4 protein is overexpressed in sarcomas. The majority of studies that have evaluated sarcoma 
MDM4 expression levels have done so through quantification of mRNA. As MDM4 mRNA expression 
was recently shown not to correlate with protein expression in freshly isolated human melanomas4, 
these previous studies may have grossly underestimated the frequency of MDM4 protein expression in 
sarcomas. Indeed, MDM4 mRNA overexpression was not observed in our previous cohort of 24 sarcoma 
tissues19. As such, MDM4 protein expression in a cohort of 36 sarcoma samples of varying histopathol-
ogy was determined through immunohistochemical analysis (IHC). Although MDM4 expression was 
very low to undetectable (< 10% MDM4 positive cells) in 24/36 (66.7%) of tumour samples, strong pos-
itive staining was observed in 12/36 (33.3%) cases (Fig. 1a, Table 1). Grade III staining (> 51% positive 
MDM4 cells) was only observed in one de-differentiated liposarcoma (Tumour SE74). Interestingly, well/
de-differentiated liposarcomas and myxofibrosarcomas exhibited significantly higher levels of MDM4 
protein expression compared to the rest of the sarcoma cohort (p < 0.0001) (Fig. 1b).
Recently, Wynendaele and colleagues reported that presence of a single nucleotide polymorphism 
(SNP34091, rs4245739) located 32 nucleotides downstream of the stop codon in the 3’UTR of MDM4 
was associated with statistically significant increased MDM4 protein expression in high-grade ovar-
ian carcinomas20. This A> C transversion was reported to create a putative illegitimate target site for 
hsa-miR-191, which only recognised the 3’UTR of the MDM4-C allele resulting in decreased MDM4 
mRNA and protein expression. To determine whether SNP34091 regulates MDM4 protein expression in 
sarcomas, the 3’UTR of MDM4 was sequenced. Genotypes were as follows, 17 (47.2%) were homozygous 
for the wild-type allele (A/A), 12 (33.3%) were heterozygous (A/C) and 7 (19.4%) were homozygous 
for SNP34091 (C/C) (Table 1). Presence of the C allele was not significantly associated with decreased 
MDM4 protein expression within our sarcoma cohort (AA vs AC: P = 0.521) (AA vs CC: P = 0.624) 
(Fig. 1c).
XI-006 induces potent apoptosis in Ewing sarcoma cell lines. As amplification of MDM4 is 
frequently observed in Ewing and osteosarcomas8, the anti-tumour activity of XI-006 was evaluated in a 
panel of eleven Ewing and osteosarcoma cell lines. Sarcoma cell lines were exposed to escalating concen-
trations of XI-006 (0–10 μ M), with the degree of apoptosis determined after 24 and 48 hrs of treatment 
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through 7AAD staining and flow cytometry. A pronounced reduction in cell viability was observed 
specifically in Ewing sarcoma cell lines at low micro-molar concentrations (Table 2, Fig. 2a). Following 
treatment, concentrations of XI-006 required to induce 50% apoptosis (IC50) in Ewing sarcoma cell 
lines ranged from 0.376–2.46 μ M and 0.099–1.61 μ M, 24 and 48 hr treatment respectively. In contrast, 
osteosarcoma cell lines required significantly higher levels of XI-006 (P = 0.008) to achieve an IC50, 
range of 3.60–> 10 μ M and 2.14–5.41 μ M, 24 and 48 hr treatment respectively (Fig. 2b). Importantly, the 
viability of normal human fibroblasts (IMR90) remained unaffected at these low micro-molar concen-



















































































Figure 1. MDM4 protein is overexpressed in sarcomas a) Representative images of sarcoma MDM4 
immunohistochemical staining. MDM4 grading determined from the average number of MDM4 positive 
cells from four fields of view, Grade 0 (< 10% positive cells), Grade I (11–25% positive cells), Grade 
II (26–50% positive cells), Grade III (> 51% positive cells) Scale bar=100uM. (b) Correlation between 
sarcoma pathology and percentage positive MDM4 cells determined from immunohistochemical analysis. 
Asterisk denotes statistical significance in MDM4 expression (****P < 0.0001). (c) Lack of correlation 
between MDM4 SNP34091 genotype (AA, AC, CC) and percentage positive MDM4 cells determined from 
immunohistochemical analysis. 
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assays were performed to investigate the long term effect of XI-006 on cellular proliferation. Following 
10 days of XI-006 treatment, no colonies were observed at any XI-006 concentration exceeding 0.03 μ M 
in TC252 and RD-ES Ewing sarcoma cell lines, and 0.11 μ M in U20S and SJSA osteosarcoma cell lines 
(Supplementary Fig. S1a,b). In contrast, numerous colonies were observed at the maximum XI-006 con-
centration tested (3 μ M) in IMR90 fibroblasts (Supplementary Fig. S1c), highlighting the tumour specific 
effect of XI-006.
To examine the cellular outcome following XI-006 treatment, cell lines were treated with XI-006 for 
48 hrs, with cell cycle distribution determined through propidium iodide (PI) staining (Supplementary 
Fig. S2). In the Ewing sarcoma cell lines TC252 and RD-ES, XI-006 induced a dose-dependent decrease 













SE74* M De-differentiated liposarcoma 51.8 ± 2.3 3 A/A
SE73 M Well-differentiated liposarcoma 36.2 ± 5.4 2 A/A
SE10* M Well-differentiated liposarcoma 30.2 ± 1.8 2 A/C
SE18* M Myxofibrosacroma 28.8 ± 2.5 2 C/C
SE31 F Undifferentiated pleomorphic sarcoma 23.8 ± 5.1 1 A/A
SE13* F Myxofibrosacroma 23.6 ± 3.7 1 A/C
SE15* F Myxofibrosacroma 18.3 ± 1.7 1 A/A
SE1 M Myxofibrosacroma 17.7 ± 2.0 1 C/C
SE27* F Radiation induced sarcoma 16.5 ± 1.9 1 A/A
SE61* M Well-differentiated liposarcoma 15.4 ± 2.6 1 A/A
SE7* M Pleomorphic liposarcoma 12.9 ± 2.8 1 A/C
SE24* M Leiomyosarcoma 10.7 ± 4.0 1 A/C
SE35* M Myxoid liposarcoma 6.1 ± 1.5 0 A/C
SE72* M Undifferentiated pleomorphic sarcoma 5.8 ± 2.3 0 A/A
SE39* M De-differentiated liposarcoma 4.1 ± 2.3 0 A/A
SE54 M Well-differentiated liposarcoma 3.5 ± 1.0 0 C/C
SE58* F Myxofibrosacroma 3.2 ± 1.4 0 A/A
SE100 M Chondrosarcoma 2.6 ± 0.6 0 A/C
SE43* F Undifferentiated pleomorphic sarcoma 2.5 ± 1.3 0 A/A
SE108 F Undifferentiated pleomorphic sarcoma 2.4 ± 2.0 0 C/C
SE66 F Leiomyosarcoma 1.9 ± 1.0 0 A/C
SE115 F Leiomyosarcoma 1.7 ± 1.0 0 A/A
SE105 M Synovial Sarcoma 1.5 ± 0.8 0 A/A
SE69* M Undifferentiated pleomorphic sarcoma 0.7 ± 0.7 0 A/C
SE79* F Undifferentiated pleomorphic sarcoma 0.6 ± 0.0 0 C/C
SE51* F Osteosarcoma 0.5 ± 0.5 0 A/A
SE52* F Leiomyosarcoma 0.4 ± 0.2 0 A/C
SE41* M Ewing sarcoma 0.3 ± 0.2 0 A/C
SE104 M Undifferentiated pleomorphic sarcoma 0.3 ± 0.3 0 A/C
SE88 M Osteosarcoma 0.3 ± 0.2 0 A/A
SE86 F Undifferentiated pleomorphic sarcoma 0.3 ± 0.2 0 A/A
SE3 F Undifferentiated pleomorphic sarcoma 0.2 ± 0.2 0 C/C
SE83 M Leiomyosarcoma 0.2 ± 0.2 0 A/C
SE47* M Angiosarcoma 0.2 ± 0.2 0 A/A
SE77 M Synovial sarcoma 0.0 ± 0.0 0 C/C
SE45 M Leiomyosarcoma 0.0 ± 0.0 0 A/A
Table 1.  Clinical characteristics and MDM4 SNP34091 genotype of the sarcoma cohort. MDM4 IHC 
Grade 0 (< 10% positive cells), Grade I (11–25% positive cells), Grade II (26–50% positive cells), Grade III 
(> 51% positive cells). * Denotes sarcoma samples previously described in Pishas et al., 2014.
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arrested cell cycle progression in osteosarcoma cell lines (U20S, Saos-2), depleting the G1 compartment 
to 18.6–19.9% and increasing the G2 compartment to 45.7–61.5% (3 μ M treatment).
MDM4 mRNA and protein levels do not confer sensitivity to XI-006. As XI-006 was shown to 
decrease MDM4 expression in breast cancer cell lines18, we investigated the effects of XI-006 on both 
MDM4 mRNA and protein levels in cell lines with varying MDM4 genomic21, mRNA and protein expres-
sion levels (Table 2, Fig. 2f). A maximum 61.2% reduction in MDM4 mRNA expression was observed 
in U20S cells (2.5 μ M, 4 hrs) following XI-006 treatment; however U20S cells were the least sensitive cell 
line to XI-006 (Fig. 2c). Although XI-006 did not attenuate MDM4 mRNA levels in the sensitive Ewing 
sarcoma cell line TC252, a 23.1% reduction was observed in WE-68 cells (0.5 μ M, 12 hrs), the least sen-
sitive Ewing sarcoma cell line. Consistent with these findings, a dose-dependent reduction in MDM4 
protein levels following XI-006 treatment was only observed in U20S and WE-68 cells, but not TC252 
cells (Fig. 2d). We next determined whether basal MDM4 mRNA and protein levels in our cohort of cell 
lines confers sensitivity to XI-006. Unexpectedly, no correlation between MDM4 mRNA or protein levels 
and XI-006 sensitivity was observed (R2 = 0.0005) (Table  2, Fig.  2e,f). To confirm whether XI-006 can 
repress MDM4 promoter activity, luciferase assays of U20S cells treated with escalating concentrations of 
XI-006 for 6 hrs were performed. A significant decrease in MDM4 promoter activity was only observed 
at 4 μ M (P = 0.05), equating to a 30.5% reduction in activity (Fig. 2g). No effect on p21 promoter activity 
was observed at this dose (P = 0.491) (Fig.  2h). As X1-006 had no effect on MDM4 promoter activity 
or mRNA/protein levels at concentrations required to induce 50% apoptosis in the most sensitive Ewing 
sarcoma cell lines (< 0.5 μ M), this suggest that the ability of XI-006 to impart apoptosis occurs inde-
pendently of MDM4.
XI-006 cytotoxicity occurs independently of TP53. We next examined whether XI-006 can induce 
expression of TP53 target genes implicated in apoptosis (BAX, PUMA), cell cycle arrest (CDKN1A) and 
p53 regulation (MDM2). Wild-type TP53 Ewing (TC252, STA-ET-1, WE-68) and osteosarcoma (U20S, 
SJSA) cell lines were treated with XI-006 (0.5, 2.5 μ M), with target gene expression assessed through 
real-time qPCR assays (Supplementary Fig. S3a). XI-006 dramatically increased mRNA expression levels 
of all TP53 target genes in Ewing sarcoma cell lines in a dose and time dependent manner. A maximum 
63 fold increase in BBC3 levels was observed in STA-ET-1 cells (2.5 μ M, 4 hrs). In contrast, induction of 
these target genes was significantly lower in all osteosarcoma cell lines, in particular BAX and CDKN1A, 
where no induction was observed for all time points and XI-006 concentrations.
To determine whether induction of p53 target genes specifically in Ewing sarcoma cells could be 
attributed to activation and stabilisation of p53, p53 protein levels following XI-006 treatment were 
examined. Activation and stabilisation of p53 protein levels was only observed in TC252 and WE-68 
Ewing sarcoma cell lines but not U20S cells following 4 hrs of XI-006 treatment (Fig. 2d). Furthermore, 
phosphorylation of p53 at serine 15 which is synonymous with ATM dependent activation of the DNA 
damage pathway22 was observed at XI-006 concentrations exceeding 0.5 μ M. Although XI-006 induced 
expression of TP53 target genes, the cytotoxic effects of XI-006 were shown to be TP53 independent, as 
XI-006 sensitivity was not correlated with TP53 status (P = 0.190) (Supplementary Fig. S3b). Indeed, the 






XI-006 IC50 (nM, 
48 hr)
STA-ET-1 ES Wild-type 1.68 ± 0.03 376.3 ± 26.9 98.9 ± 19.5
TC252 ES Wild-type 2.74 ± 0.04 390.2 ± 106.6 115.6 ± 6.6
SK-N-MC ES Truncation 0.61 ± 0.00 472.3 ± 176.4 121.8 ± 31.7
SK-ES-1 ES Cys176Phe 0.70 ± 0.01 442.4 ± 57.5 236.0 ± 15.0
RD-ES ES Arg273Cys 0.32 ± 0.00 638.9 ± 142.4 299.7 ± 68.5
TC71 ES Truncation 0.40 ± 0.02 567.9 ± 150.8 396.1 ± 78.8
WE-68 ES Wild-type 1.09 ± 0.04 2089.3 ± 20.4 1475.7 ± 222.6
VH-64 ES Wild-type 1.07 ± 0.01 2456.4 ± 315.1 1613.1 ± 274.4
Saos-2 OS Null 0.17 ± 0.00 3600.2 ± 525.7 2143.0 ± 34.9
SJSA OS Wild-type 0.15 ± 0.01 6257.1 ± 366.5 3690.5 ± 270.2
U20S OS Wild-type 1.94 ± 0.04 > 10 000 5416.8 ± 255.7
IMR90 LFB Wild-type — 8348.0 ± 231.0 6802.1 ± 696.5
Table 2.  XI-006 IC50 values of the sarcoma cell line cohort. ES: Ewing sarcoma, OS: Osteosarcoma, 
LFB: Lung fibroblast IC50: Concentration of XI-006 required to induce 50% apoptosis (mean ± STDEV from 
two independent experiments). MDM4 mRNA expression determined through real-time qPCR analysis 
(mean ± SE from triplicate reactions).
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Figure 2. MDM4 mRNA and protein levels do not confer XI-006 sensitivity (a) XI-006 apoptotic 
dose response curves of all sarcoma cell lines following 48 hrs of XI-006 treatment. Dashed and red lines 
denote osteosarcoma and mutant TP53/null cell lines respectively. Data represents mean ± STDEV from 
two independent experiments, duplicate reactions. (b) Correlation between XI-006 apoptotic 48 hr IC50 
values determined from 7AAD staining and sarcoma pathology. (c) STA-ET-1, TC252, WE-68 and U20S 
cells were treated with XI-006 (0, 2.5 and 5 μ M) for the indicated times with mRNA expression levels of 
MDM4 determined through real-time qPCR analysis. Data represents mean expression (fold change) ± SE 
from triplicate reactions. (d) TC252, WE-68 and U20S cell lines were treated for 4 hrs with the indicated 
concentrations of XI-006. MDM4, p53, and phosphorylated p53 (serine 15) protein levels were detected 
through western blot analysis. β − Actin was used a loading control. (e) Lack of correlation between XI-006 
apoptotic 48 hr IC50 values and basal MDM4 mRNA expression levels. ◆� Denotes Ewing sarcoma and 
osteosarcoma cell lines respectively. (f) Western blot analysis of basal MDM4 protein levels of the cell line 
cohort. Cell lines ranked in order of XI-006 sensitivity. MCF-7 (MDM4 amplified breast cancer cell line) 
was used as a positive control. Luciferase assay of (g) MDM4 and (h) p21 promoter activity from U20S cells 
treated with XI-006 for 6 hrs. Data represents mean ± SE from 3 independent experiments. Asterisk denotes 
statistical significance (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001).
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least sensitive Ewing (WE-68, VH-64) and osteosarcoma (U20S, SJSA) cell lines harboured wild-type p53 
(Table 2). To further examine the role of TP53 in XI-006 cytotoxicity, TP53 wild-type and null HCT116 
isogenic cell lines were treated with XI-006 (0–10 μ M) (Supplementary Fig. S3c). No significant differ-
ence in both XI-006 IC50 values (24 hr: P = 0.230, 48 hr: P = 0.505) or relative viability at any concentra-
tion tested was observed, endorsing the p53-independent cytotoxic effects of XI-006.
Low micro-molar concentrations of XI-006 do not induce DNA damage. Previous reports pro-
posed that XI-006 activates the DNA damage response pathway leading to a delay in cell cycle progres-
sion23. As XI-006 cytotoxicity occurs independently of MDM4, we sought to address whether XI-006 
drives apoptosis through DNA damage. Clustering of phosphorylated H2AX moieties (γ H2AX foci) at 
the site of double-strand breaks (DSBs) is one of the earliest events indicative of DNA damage24. Indeed 
a dose dependent increase in γ H2AX foci was detected through immunofluorescence analysis following 
4 hrs of XI-006 treatment in TC252 and U20S cells (Fig. 3a). At 4 μ M 64.7–79.3% of cells (TC252 and 
U20S respectively) displayed > 5 positive γ H2AX foci. However at low doses required to induce apop-
tosis in the most sensitive Ewing sarcoma cell lines (0.5 μ M), positive γ H2AX foci were only detected in 
9.9–17.4% of cells (Fig. 3b). In agreement with these findings XI-006 induced γ H2AX foci formation was 
correlated with H2AX phosphorylation (Fig. 3c). Neutral comet assays were also employed to determine 
whether low dose XI-006 (0.075, 0.150, 0.300 μ M) induces DSB’s following long term exposure (20 hrs) 
n TC252 and RD-ES cells (Fig. 3d). No significant difference in comet tail length was observed in com-
parison to vehicle control treated cells at any XI-006 concentration tested (Fig. 3e).
The serine/threonine protein kinase ATM (ataxia telangiectasia mutated) is critical for sensing and 
co-ordinating repair of DNA DSBs. To further confirm that the cytotoxic effects of XI-006 was not due 
to DNA damage at low concentrations, Ewing cells (TC252, RD-ES and WE-68) were pre-treated with 
the ATM inhibitor KU-55933, before the addition of XI-006 (0.02–5 μ M). A significant reduction in both 
ATM and ATR mRNA expression (82.0% and 87.5% respectively) was observed following monotherapy 
KU-55933 treatment (5 μ M) (Supplementary Fig. S4a,b). No significant difference in XI-006 apoptotic 
IC50 values (24 and 48 hr treatment) was observed following ATM inhibition across all cell lines tested 
(Supplementary Fig. S4c).
Previous chemogenomic profiling studies suggested that XI-006 imparts its cytotoxic effect through 
the activation of the DNA-damage-response pathway. Phosphorylation of the N-terminal domain of 
EWS-FLI1, the hallmark gene fusion of Ewing sarcoma, at Thr25 has been reported in response to mito-
gen or DNA alkylating agent induced DNA damage26. This post-translational modification was found to 
be catalysed by p38α /p38β mitogen-activated protein kinases (MAPKs). As all Ewing sarcoma cell lines 
utilised in this study harbour the EWS-FLI1 fusion, we examined the role p38α /p38β MAPKs in XI-006 
sensitivity. TC252 and RD-ES cells were pre-treated with the p38α /p38β MAPK inhibitor BIRB 796 (0.1, 
1 and 10 μ M) before the addition of XI-006 (0–2.5 μ M) for 24 and 48 hrs. BIRB 796 was previously shown 
to inhibit p38α /p38β MAPKs specifically at 0.1 μ M, p38y/p38δ MAPKs at 1 μ M and completely suppress 
the activation and activity of all JNKs at 10 μ M26 in Ewing cell lines. Treatment with BIRB 796 had no 
effect on XI-006 induced cytotoxicity (24 and 48 hrs), as a significant reduction in apoptosis (> 30%) was 
not observed at any BIRB 796 concentration (Supplementary Fig. S5).
Finally, alkaline comet assays were employed to investigate whether XI-006 induces single-strand 
break DNA damage. Following 4 hrs of XI-006 treatment, a significant increase in comet tail and length 
was only observed at concentrations exceeding 2 μ M (Fig.  4). Collectively these results suggest that 
XI-006 concentrations (< 0.5 μ M) required to induce apoptosis in sensitive Ewing sarcoma cells lines 
cannot be attributed to a DNA damage mechanism of action
XI-006 synergises with olaparib, actinomycin D, doxorubicin and etoposide. As conventional 
single-agent cancer therapy increases the likelihood of the emergence of resistant cancer cell clones, 
combination therapies are required to achieve maximal therapeutic response. As such, the ability of 
XI-006 to enhance the cytotoxic effects of four standard Ewing sarcoma chemotherapeutic agents 
(vincristine, actinomycin D, doxorubicin or etoposide) was assessed in five Ewing sarcoma cell lines 
(TC252, STA-ET-1, WE-68, RD-ES, and SK-N-MC). Modest synergistic combination indexes (CI < 1) 
were observed in 4/5 cell lines for actinomycin and doxorubicin and 3/5 cell lines tested for etoposide 
(CI range 0.753–0.989) over multiple chemotherapeutic doses (Supplementary Table S2, Supplementary 
Fig. S6). Although antagonistic CI values were obtained between XI-006 and vincristine (inhibitor of 
microtubule assembly), a strong correlation (R2 = 0.722) was observed between XI-006 and vincristine 
IC50 values in all Ewing sarcoma cell lines, suggesting that these two agents may have a similar mecha-
nism of action (Supplementary Fig. S7).
The EWS-FLI fusion protein has been shown to drive expression of PARP1 (poly-ADP-ribose pol-
ymerase), which subsequently further promotes transcriptional activation by EWS-FLI27. The primary 
function of PARP is to sense and mediate repair of DNA single strand breaks (SSB). Therefore we 
determined if XI-006 can synergise with olaparib (PARP inhibitor) in EWS-FLI positive Ewing sarcoma 
cell lines. TC252, RD-ES and WE-68 cells were pre-treated with olaparib prior to addition of XI-006 
(0–5 μ M). Potent synergy between these two agents was observed in all cell lines tested and across multi-
ple XI-006 concentrations, 24 and 48 hrs post XI-006 treatment. A maximum 51.9% increase in apoptosis 
was observed in RD-ES cells when these two agents were combined (48 hr XI-006 treatment) (Fig. 5a). 
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Figure 3. XI-006 does not induce double-strand break DNA damage at low micro-molar concentrations 
(a) Representative images of γ H2AX foci formation (immunofluorescence) from TC252 and U20S 
cells treated with the indicated concentrations of XI-006 for 4 hrs. Cells were stained with DAPI (blue) 
and γ H2AX (green). (b) Percent nuclei positive for γ H2AX foci (> 5) from cells treated as in (a) 
(mean ± STDEV from duplicate wells). (c) Western blot analysis of γ H2AX protein levels in TC252 cells 
treated as in (a). β -Actin was used as the loading control. (d) Representative images of neutral comet 
assays from TC252 and RDES cells treated with low dose XI-006 (0.075, 0.150, 0.300 μ M) for 20 hrs. (e) 
Quantification of tail length from cells treated as in (d), mean ± SE.
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Olaparib did not abrogate the cytotoxic effects of XI-006 at any concentration tested, suggesting that 
XI-006 does not induce DNA damage via single stranded breaks at low doses.
In addition to repair of SSB, PARP detects stalled replication forks and attracts Mre11 (meiotic recom-
bination 11) for end processing to facilitate replication restart and recombination repair28. As XI-006 
was previously shown to induce a significant delay in replication23, Mre11 mRNA expression levels fol-
lowing XI-006 treatment was assessed. A decrease in Mre11 mRNA expression was observed across all 
cell lines tested, with a maximum 50.1% reduction observed in STA-ET-1 cells (8 hr treatment) (Fig. 5b, 
Supplementary Fig. S8). As PARP mediates the recruitment Mre11 to stalled replication forks, Mre11 
expression in RD-ES pre-treated with olaparib (1 μ M) before the addition of XI-006 was assessed. 
Olaparib treatment alone resulted in a significant 25% decrease in Mre11 mRNA expression (Fig.  5c). 
Co-treatment with XI-006 (0.5 and 1 μ M) further repressed Mre11 mRNA expression levels, maximum 
50.4% reduction compared to XI-006 treatment alone observed. Together, these findings indicate that 
in the absence of DNA damage low micro-molar concentrations of XI-006 can potentiate the cytotoxic 
effects of olaparib due to down-regulation of Mre11 expression.
HEG1, FLOT1, UTRN and EDIL3 are differentially expressed in Ewing and osteosarcoma 
cells following XI-006 treatment. mRNA sequencing of XI-006 treated and untreated cell lines 
was employed to identify genes responsible for XI-006 cytotoxicity. Across all Ewing and osteosarcoma 
cell lines eleven genes were found to be either significantly (P < 0.05, Bonferroni correction) repressed 
(KIF20A, IDH1, SCD, GPSM2, EIF2AK4, HIBCH) or induced (STK19, DNAJC24, MTG2, FAM175B, 
CYB5D1) following non DNA-damaging XI-006 treatment (0.5 μ M) (Table 3). Real-time qPCR analyses 
confirmed that KIF20A which is required for normal cleavage furrow ingression and cytokinesis during 
cell division29 and IDH1 (cytosolic NADP dependent enzyme) were repressed on average by 51.2% and 
41.3% respectively across all cell lines following XI-006 treatment (Supplementary Fig. S9).
We next sought to identify genes that were differentially expressed between Ewing and osteosar-
coma cell lines following XI-006 treatment. Four genes (UTRN, HEG1, FLOT1, EDIL3) were identi-
fied and validated through real-time qPCR analysis (Table  3, Supplementary Fig. S10). Of particular 
interest UTRN which mediates several mitochondria dependent apoptosis pathways, was found to be 
Figure 4. XI-006 does not induce single-strand break DNA damage at low micro-molar concentrations 
a) Representative images of alkaline comet assays from TC252 and U20S cells treated with XI-006 (1, 2, 
4 μ M) for 4 hrs. Etoposide (ETO) was used as a positive control (b) Quantification of tail length and tail 
moment from cells treated as in (a) mean ± SE.
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Figure 5. Inhibition of PARP potentiates the cytotoxic effects of XI-006 a) TC252, RD-ES and WE-68 
were pre-treated with olaparib (0.5 or 1 μ M) or vehicle control (DMSO) for 2 hrs, prior to the addition 
of XI-006 (0–5 μ M). Cell viability was determined through 7AAD staining (24 and 48 hrs post XI-006 
treatment) and analysed by flow cytometry. Data represents average percentage cell death ± STDEV from 
duplicate reactions. Asterisk denotes significant increase in apoptosis compared to XI-006 alone (*15–30%, 
**31–45%, ***> 46% increase). (b) STA-ET-1, RDES, WE-68 and U20S cells were treated with XI-006 (0.5, 
1.25, 2.5 μ M) for 4 and 8 hrs. mRNA expression levels of Mre11 were determined through real-time qPCR 
analysis. Data represents mean expression (fold change) ± SE from triplicate reactions. (c) RD-ES cells 
were pre-treated with Olaparib for 2 hrs prior to the addition of XI-006 (0.5, 1, 2 μ M) for an additional 
4 hrs. Mre11 mRNA expression levels determined as in (b). Asterisk denotes statistical significant reduction 
in expression compared to either vehicle control (b) or XI-006 treatment alone (c) (*P < 0.05, **P < 0.01, 
***P < 0.001, ****P < 0.0001).
www.nature.com/scientificreports/
1 1Scientific RepoRts | 5:11465 | DOi: 10.1038/srep11465
significantly upregulated in Ewing cell lines (average 22.7% increase) which undergo apoptosis following 
XI-006 treatment, and repressed in osteosarcoma cell lines (average 31.9% decrease) (P = 0.025) which 
undergo cell-cycle arrest following XI-006 treatment.
Discussion
Despite the use of aggressive multi-modal therapeutic strategies, five year survival rates for relapsed 
Ewing sarcoma patients is < 30% and in such cases no standard therapy currently exists for second line 
treatment. Despite the emerging role of MDM4 (structural homologue of MDM2) in the pathogenesis, 
maintenance, and chemo-resistance of human cancer, there are currently no selective MDM4 antago-
nists undergoing clinical trial evaluation. As MDM4 gene amplification is a characteristic of both Ewing 
and osteosarcoma8, this study assessed the therapeutic potential of XI-006, a small molecule thought to 
attenuate MDM4 promoter activity, for the treatment of sarcoma. Indeed, MDM4 IHC analysis of our 
sarcoma cohort detected MDM4 protein expression (> 10 positive cells) in 33.3% (12/36) of cases and 
was highly prevalent in well/de-differentiated liposarcomas and myxofibrosarcomas (Fig. 1).
Low micro-molar concentrations of XI-006 induced rapid apoptosis specifically in Ewing sarcoma 
cell lines (IC50 0.099–1.61 μ M) in the absence of both observable DNA damage and effect on MDM4 
expression levels (Table 1, Fig. 2). Cell line sensitivity to XI-006 was not correlated with MDM4 mRNA or 
protein levels, and reduction of MDM4 mRNA and protein levels were only observed in the least sensi-
tive Ewing sarcoma and osteosarcoma cell lines at high XI-006 concentrations (> 1 μ M) that also induced 
DNA damage (Figs 3 and 4). It is known that DNA damage induces ATM/Chk2 dependent phosphoryl-
ation of several MDM4 C-terminal residues (S342, S367, S403), resulting in degradation of MDM4 and 
activation of p5325. Indeed, ATM mediated phosphorylation of serine 15 in p53 was observed in Ewing 
sarcoma cell lines following treatment with double-strand break inducing concentrations of XI-006 
(> 0.5 μ M). As only a maximum 30.5% reduction in MDM4 promoter activity was observed following 
4 μ M XI-006 treatment (Fig. 2), our findings suggest that XI-006 cytotoxicity in Ewing sarcoma cell lines 
cannot be attributed to repression of MDM4 activity.
The introduction of systemic chemotherapy in the 1960’s greatly improved survival rates for patients 
with localised Ewing sarcoma30, hence it is imperative that XI-006 can synergise with current chemo-
therapeutic protocols as well as novel agents. In addition to synergising with doxorubicin, etoposide and 
actinomycin D (CI range 0.753–0.989), a maximum 51.9% increase in apoptosis was observed when 
XI-006 was combined with the PARP inhibitor olaparib (Fig. 5).
Genes significantly induced or repressed following XI-006 across all sarcoma cell lines
Accession Number Gene Location Full Name % Change P value
NM_005733 KIF20A 5q31 Kinesin family member 20A − 44.49 0.0214
NM_005063 SCD 10q24.31 Stearoyl-CoA desaturase (delta-9-desaturase) − 38.01 0.0076
NM_005896 IDH1 2q33.3 Isocitrate dehydrogenase 1 (NADP+ ), soluble − 37.14 0.0040
NM_013296 GPSM2 1p13.3 G-protein signalling modulator − 33.34 0.0401
NM_001013703 EIF2AK4 15q15.1 Eukaryotic translation initiation factor 2 alpha kinase − 24.35 0.0034
NM_014362 HIBCH 2q32.2 3-hydroxyisobutyryl-CoA hydrolase − 16.66 0.0134
NM_004197 STK19 6p21.3 Serine/threonine kinase 19 31.43 0.0433
NM_181706 DNAJC24 11p13 DnaJ (Hsp40) homolog, superfamily C, member 24 25.99 0.0181
NM_015666 MTG2 20q13.33 Mitochondrial ribosome-associated GTPase 2 25.18 0.0040
NM_032182 FAM175B 10q26.13 Family with sequence similarity 175, member B 24.37 0.0459
NM_144607 CYB5D1 17p13.1 Cytochrome b5 domain containing 1 20.32 0.0311
Genes differentially expressed in Ewing and osteosarcoma cell lines following XI-006 treatment




% Change Osteosarcoma P value
NM_020733 HEG1 3q21.2 Heart development protein with EGF-like domains 1 4.77 − 73.76 0.00001
NM_005803 FLOT1 6p21.3 Flotillin − 5.44 − 98.73 0.0007
NM_007124 UTRN 6q24 Utrophin 2.65 − 53.96 0.0128
NM_005711 EDIL3 5q14 EGF-like repeats and discoidin I-like domains 3 − 1.01 − 110.0 0.0269
Table 3.  Genes identified from RNA expression profiling of Ewing and osteosarcoma cell lines treated 
with XI-006.
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PARP-1 is a member of the base excision repair pathway that sensors and modulates the spatial and 
temporal organization of single-strand break repair31. Inhibition of PARP-1, results in the accumulation 
of persistent single-strand breaks which are converted to lethal double-strand breaks upon replication. 
Since the 1990’s it has been known that Ewing sarcomas express high levels of PARP-132, and the prem-
ise of PARP inhibition as a therapeutic avenue for the treatment of Ewing sarcoma has been furthered 
strengthened by several key studies. Firstly, large-scale drug screening (130 compounds) in > 600 human 
cancer cell lines identified a highly significant association between EWS-FLI1, the hallmark translocation 
of Ewing sarcoma, and sensitivity to the olaparib. Indeed, FLI1 expression levels in Ewing sarcoma cell 
lines were highly correlated with olaparib sensitivity33. This study was complemented by Brenner and 
colleagues, who demonstrated that the EWS-FLI1 fusion acted in a positive feedback loop to maintain 
the expression of PARP1 which was required for EWS-FLI–mediated transcription27. Furthermore, DNA 
damage induced by expression of EWS-FLI1 was potentiated by PARP1 inhibition in vitro. As PARP1 
inhibitors have exhibited promising activity in early clinical trials34, phase I/II trials of PARP inhibitors 
(olaparib and BMN-673) are currently undergoing investigations in adults with recurrent and meta-
static Ewing sarcoma (NCT01583543), and patients with locally advanced or metastatic solid tumours 
(NCT02049593).
Previous chemogenomic profiling studies suggested that XI-006 (referred to as NSC-207895) activates 
the DNA-damage-response pathway through an indirect mechanism leading to a significant delay in 
replication and cell cycle progression23. Replication stress, defined as the slowing or stalling of replication 
fork progression and/or DNA synthesis, has severe implications for genome stability and cell survival35. 
Several studies have implicated that PARP binds to and is activated at stalled replication forks that con-
tain small gaps (< 4 nucleotides) or short ssDNA regions, and mediates the recruitment of Mre1128. 
Mre11 is a key component of the MRN (Mre11-Rad50-Nbs1) complex, which is vital for double-strand 
break (DSB) recognition, replication fork stabilization, ATM/ATR activation and the initiation of end 
resection required for replication restart and homologous recombination (HR)36. Inhibition or loss of 
PARP impairs Mre11 localisation to stalled forks, RPA and RAD51 foci formation, HR and replication 
restart. Indeed numerous studies have shown that due to impaired HR DNA repair, loss of Mre11 expres-
sion sensitizes breast37, colorectal38,39, endometrial40, and haematological cancers41 to PARP-inhibitors. In 
the absence of DNA damage, our findings demonstrate that low dose XI-006 rapidly down regulates the 
expression of Mre11 (Fig. 5) and this repression in further enhanced in the presence of olaparib (Fig. 5), 
resulting in potent apoptosis. As such, these findings provide a strong rationale for further investigations 
into the combinatorial approach of PARP inhibitors with XI-006.
To elucidate the genes specifically responsible for Ewing sarcoma apoptotic XI-006 sensitivity, mRNA 
sequencing was employed and identified four genes significantly differentially expressed between Ewing 
and osteosarcoma cell lines following XI-006 treatment (Table  3). Of particular relevance, UTRN 
(Utrophin) was significantly upregulated in Ewing sarcoma cell lines but repressed in osteosarcoma cell 
lines (P = 0.025). The GTPase UTRN also known as Drip1, mediates outer mitochondrial membrane 
fission and is essential for the normal progression of several mitochondria dependent apoptosis path-
ways42. Upon induction of apoptosis, UTRN is recruited from the cytosol to the mitochondrial outer 
membrane, where it colocalizes with Bax at fission sites and mediates the release of apoptotic regulatory 
proteins including cytochrome c prior to caspase activation43,44. The expression of FLOT1 (flotillin) was 
also significantly repressed in osteosarcoma cell lines (P = 0.044) compared to Ewing. The flotillin family 
of proteins have been implicated in numerous cellular processes such as actin-cytoskeleton reorganiza-
tion, endocytosis, adhesion and transduction of cellular signals45. Knockdown of FLOT1 has been shown 
to significantly impair cell proliferation and tumourigenicity of breast and esophageal squamous cell 
carcinoma cells in vitro and in vivo through the Akt/FOXO3a pathways46,47. Indeed, silencing of FLOT1 
induced G1-S-phase arrest of breast cancer cells due to upregulated expression of the CDK inhibitors 
p21Cip1 and p27Kip1. Following XI-006 treatment, both UTRN and FLOT1 were strongly repressed in oste-
osarcoma cell lines (31.9% and 33.8% decrease in mRNA expression respectively) but not in Ewing cell 
lines. This may be the basis of the finding that XI-006 induces apoptosis in Ewing sarcoma cell lines but 
cell cycle arrest in osteosarcoma cell lines (Supplementary Fig. S2).
Expression profiling also revealed that following XI-006 treatment, eleven genes were globally 
repressed or induced across all Ewing and osteosarcoma cell lines. Three of these genes which were 
downregulated, KIF20A, IDH1 and GPSM2 (44.49%, 37.14% and 33.34% reduction respectively), have 
been implicated in cell proliferation. KIF20A belongs to the family of kinesin microtubule-dependent 
motor proteins, which are required for bipolar spindle assembly, chromosome alignment, chromo-
some segregation, and cytokinesis48. Similarly GPSM2 is required for spindle cell orientation towards 
the interphase long-axis49. Several studies have demonstrated the essential role of KIF20A in cytoki-
nesis and maintenance of cell viability. Microinjection of anti-KIF20A antibody was shown to induce 
multi-nucleation in Hela cells50 and knockdown of endogenous KIF20A expression markedly attenuated 
the growth of pancreatic and gastric cancer cells51,52. As sensitivity to XI-006 was strongly correlated with 
vincristine sensitivity (R2 = 0.722) (Supplementary Fig. S7), a widely used chemotherapeutic that inhibits 
microtubule assembly and induces tubulin self-association into coiled spiral aggregates53, this supports 
that the mechanism of action of XI-006 at low, micro-molar concentrations (< 0.5 μ M) can be attributed 
to inhibition of cell division and cycle regulators and not DNA damage.
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In summary, our findings demonstrate that XI-006 is a promising new potential therapeutic for the 
treatment of Ewing sarcoma as it induced potent p53-independent apoptosis at non-DNA damaging con-
centrations specifically in Ewing sarcoma cell lines. Notably, strong synergy was observed with olaparib, a 
PARP inhibitor that is gaining significant interest for the treatment of solid cancers. As such, our preclin-
ical findings warrant further pharmacokinetic and pharmacodynamic investigations of XI-006 in vivo.
Methods
Cell lines and reagents. Ewing sarcoma cell lines were cultured as previously described21 and supplied by 
G. Hamilton (University of Vienna, Austria) (TC252, TC71), F. van Valen (Westfälische-Wilhelms-University, 
Germany) (WE-68, VH-64), P. Ambros (St. Anna Children’s Hospital, Austria) (STA-ET-1) and V. Russo 
(Murdoch Children’s Research Institute, Australia) (SK-N-MC). SK-ES-1, RD-ES cell lines were purchased 
from American Type Tissue Culture. Osteosarcoma cells (SJSA, U20S and Soas-2) were supplied by A. 
Evdokiou (University of Adelaide, Australia).
XI-006 and BIRB 796 were purchased from Merck Millipore, KU-55933 and olaparib (AZD2281) 
were purchased from Selleck. Vincristine sulfate (Hospira), doxorubicin HCI (Pfizer), actinomycin D/
Cosmegen (Lundbeck) and etoposide (Royal Adelaide Hospital, Australia) were supplied by M.P Brown 
(Centre for Cancer Biology, Australia).
Sarcoma tissue cohort. Chemotherapy/radiotherapy naïve tumour specimens were collected from 
thirty-six patients with sarcoma (22 males, 14 females) undergoing surgical resection/core biopsy at 
three clinical institutions; Royal Adelaide Hospital (RAH), Calvary Wakefield Hospital, and St Andrew’s 
Hospital between 2010 and 2013. Patient consent was obtained for accrual of surgically excised tissue. 
Study was approved by the Royal Adelaide Hospital Human Ethics Committee (RAH Protocol #100505). 
The different morphological subtypes were represented by nine undifferentiated pleormorphic sarco-
mas, eight liposarcomas (four well-differentiated, two de-differentiated, one pleomorphic and myxoid), 
six leiomyosarcomas, five myxofibrosarcomas, two osteosarcomas, two synovial and one Ewing sar-
coma, angiosarcoma, chondrosarcoma and radiation induced sarcoma. Twenty patients were previously 
described19. All methods were carried out in accordance with National Health and Medical Research 
(NHMRC) approved guidelines.
Immunohistochemistry. MDM4 immunohistochemical protocol was adapted from54. Briefly, FFPE 
(4 μ m thickness) were deparaffinised by serial immersion in a xylene-to-ethanol solvent gradient. After 
citrate buffer (0.001 mol/L, pH 6.0) antigen retrieval, slides were quenched in 3% hydrogen peroxide 
for 5 mins to eliminate endogenous peroxidase activity. Sections were blocked with normal goat serum 
(30 mins) and immuno-labelled with rabbit HdmX/MDM4 (1:250, IHC-00108, Bethyl Laboratories) 
overnight at 4 °C. Digital images were acquired using a Nanozoomer Digital Pathology Scanner, at x40 
magnification. To determine the percentage of positive MDM4 cells, a minimum of 80 cells per field of 
view (four) were assessed.
MDM4 SNP34091 genotype analysis. DNA from sarcoma tissues was isolated using the DNeasy 
Blood and Tissue Kit (Qiagen) according to the manufacturer’s instructions. The 3’UTR region of MDM4 
was amplified using the following primer pair55 forward: 5′ ACGGGCCATCTTGTCACTTGTT 3′ and 
reverse: 5′ ACCTGACTGCT GCATAAAGTAATCCAT 3′ , to amplify a 355 base pair (bp) product. PCR 
was performed using 100 ng of genomic DNA and FastStart Taq DNA Polymerase (Roche) using the 
following parameters, enzyme activation 95 °C 3 mins, followed by 45 cycles of denaturation at 95 °C 
30 secs, annealing at 57 °C 15 secs, and extension at 72 °C 60 secs, followed by 1 cycle of final extension 
at 72 °C 10 mins. Reactions were processed on an ABI Hitachi 3730 DNA analyser.
Apoptosis and Cell cycle analysis. For viability assays, cell were seeded in 96-well micro-titer plates 
at a density of 3 × 104 cells/well and treated with XI-006 alone or in combination with chemotherapeutics 
agents. For inhibitor studies, cells were pre-treated with olaparib, KU-55933 or BIRB 796 for 2 hrs prior 
to the addition of XI-006. Following treatment for 24 and/or 48 hrs, cells were centrifuged at 2500 rpm 
for 5 mins, washed in phosphate buffered saline (PBS) and stained with 7-amino-actinomycin-D solution 
(7AAD, 2 mg/mL, Invitrogen) for 10 mins at room temperature.
For cell cycle analysis, XI-006 and vehicle control treated cells were permeabilized with cold 70% eth-
anol overnight, and stained with a solution containing 50 μ g/ml propidium iodide (PI, Sigma Aldrich), 
0.05% Triton-X and 100 μ g/ml RNase A at 37 °C for 40 mins. Cell viability and DNA content was deter-
mined through the use of a FACS Calibur flow cytometer (Becton-Dickinson Immunocytometry Systems) 
with cell cycle profiles and viability analyzed using FLOWJO software (V7.6.5).
Luciferase Assay. U20S cells (3.2 × 104) were seeded overnight in 24-well plates (triplicate wells per 
treatment) and transfected with 200 ng of pCM-luci-MDM4 or p21-pro-Luc reporter constructs and 
25 ng of pRL-TK plasmid (Promega) using Lipofectamine LTX (Invitrogen) according to the manufac-
turers’ instructions. pCM-Luci-MDM4 was kindly supplied by C. Yan (GRU Cancer Center). Cells were 
treated with vehicle control or XI-006 for 6 hrs with Dual-luciferase reporter assays (Promega) performed 
according to the manufacturer’s instructions.
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Real-time qPCR analysis. Total RNA was extracted using RNeasy mini kit (Qiagen), using on-column 
RNase-free DNase digestion according to the manufacturer’s instructions. cDNA was synthesized by 
reverse transcribing 600 ng of total RNA using random primers (Promega) and Moloney murine leu-
kemia virus reverse transcriptase (H_; Promega). Real-time qPCR reactions were performed using iTaq 
Universal Sybr Green Supermix (BIORAD) and processed on a CFX Real-Time PCR detection system 
(BIORAD). Cycling parameters were as follows: 95 °C for 3 mins, followed by 45 cycles of denaturation 
at 95 °C for 10 secs, annealing at 59–63 °C for 15 secs, and extension at 72 °C for 30 secs. Relative target 
mRNA expression was determined using the Δ CT method from triplicate reactions, with the levels 
of gene expression normalized to the relative average Ct value of Peptidylprolyl Isomerase-G (PPIG). 
Primer sequences and annealing temperatures are listed in Supplementary Table S1.
Western blot. Western blot analysis was performed as previously described21. Whole protein lysates 
(5–20 μ g) were resolved using SDS PAGE electrophoresis, and probed overnight at 4 °C with the follow-
ing primary antibodies MDM4 (1:500; A300-287A, Bethyl Laboratories), p53 DO1 (1:1000, Santa Cruz 
Biotechnology), Phospho-p53 (Ser15) (1:500, Cell Signalling), Phospho-Histone H2A.X (Ser139) clone 
JBW301 (1:500, Millipore) and β -Actin (1:1000, AC-15, Sigma).
Immunofluorescence. TC252 and U20S cells (1.5 × 104 cells per 6 well chamber) were seeded on 
microscopes slides and treated with XI-006 (0.5, 1, 2 and 4 μ M) or vehicle control (DMSO) for 4 hrs. Cells 
were fixed with 10% neutral-buffered formalin, washed with PBS and blocked with 5% bovine albumin 
serum with 0.3% Triton-X 100 (Sigma-Aldrich). Slides were washed in PBS (3 × 5 min), then incubated 
with 1 μ g/ml biotinylated mouse anti-human anti-phospho-histone H2AX (ser139) (JBW301, Millipore) 
overnight at 4 °C. After further washing, samples were incubated with 5 μ g/ml streptavidin-Alexa Fluor 
488 (Life Technologies) followed by counterstaining with 1 μ g/ml DAPI. Slides were examined using 
an Olympus IX71 microscope (x40 magnification) with CellSens Standard (v1.6) software. Images were 
analysed using ImageJ (v1.45) (National Institute of Health).
Comet Assay. Neutral and alkaline comet assays were performed with the Trevigen CometAssay kit 
according to the manufacturer’s protocol. Briefly, 3.5 × 105 cells were plated in 6 well plates and treated 
with XI-006 or vehicle control for 4 or 20 hrs. Lysed cells were subjected to electrophoresis for 40 mins at 
30 V (300 mA) at 4 °C. Cells were stained with 2.5 μ g/ml PI for 15 mins and visualised with an Olympus 
IX71 microscope (x20 magnification) with CellSens Standard (v1.6) software. Tail length and moment 
were assessed using AutoComet software (TriTek) from a minimum of 60 cells.
mRNA sequencing. Ewing and osteosarcoma cell lines (n = 11) were treated with XI-006 (0.5 μ M) 
or vehicle control for 4 hrs. One μ g of RNA was used for polyA selection and library construction with 
NEBNext UltraT RNA Library Prep Kits for Illumina sequencing, according to the manufacturer’s 
instructions (E7530 Version 2). The mRNA library size was validated with the Agilent BioAnalyzer on 
High Sensitivity chips, with yield determined with a Life Technologies Qubit 2.0 Fluorometer. The mRNA 
libraries were pooled and sequenced across five lanes of an Illumina HiSeq 2500 flowcell (1 × 50 bp 
reads) at the Australian Cancer Research Foundation Cancer Genomics Facility (Adelaide, Australia). 
Reads were trimmed for the NEB single end adapter “AGATCGGAAGAGCACACGTCTGAACTCCAG 
TCAC” with Cutadapt v1.3, requiring a minimum overlap of 5, allowing a 20% error rate and discard-
ing trimmed sequences shorter than 18 bases. Reads were mapped to the UCSC hg19 genome and GTF 
annotations with Tophat 2.0.9 using default parameters. Gene counts were performed with HTSeq-count 
v0.6.1p1 using gene_id as the GTF feature ID.
Statistics. Combination Index (CI) values were used to determine synergy between XI-006 and cyto-
toxic agents. A CI value of < 1, = 1 and > 1 indicates synergistic, additive and antagonistic effects respec-
tively56. P values were calculated using Student t test using Graph Pad Prism Version 6.
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